Xenetic Biosciences (XBIO) Accounts Payables (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Accounts Payables came in at $558808.0 in Q1 2026, up 6885.1% YoY from $8000.0 in Q1 2025, and up 116.5% on a QoQ basis from $258109.0 in Q4 2025.
Xenetic Biosciences (XBIO) Accounts Payables (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Accounts Payables data on file, last reported at $558808.0 in Q1 2026.
- Quarterly Accounts Payables rose 6885.1% year-over-year to $558808.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $558808.0 (up 6885.1% YoY) and the FY2025 annual result came in at $258109.0, down 8.99% from the prior year.
- Accounts Payables improved to $558808.0 in Q1 2026, from $258109.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $578250.0 in Q3 2025 to a low of $8000.0 in Q1 2025.
- A 5-year average of $304964.1 and a median of $280680.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables tumbled 96.2% — and 2026, when it surged 6885.1%.
- Tracing XBIO's Accounts Payables over 5 years: stood at $287360.0 in 2022, then slipped by 16.19% to $240832.0 in 2023, then gained by 17.76% to $283615.0 in 2024, then dropped by 8.99% to $258109.0 in 2025, then surged by 116.5% to $558808.0 in 2026.
- The last three Accounts Payables figures came in at $558808.0 (Q1 2026), $258109.0 (Q4 2025), and $578250.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 322,537.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 322,537.00 |
| Mar 31, 2026 | 558,808.00 |
| Dec 31, 2025 | 258,109.00 |
| Sep 30, 2025 | 578,250.00 |
| Jun 30, 2025 | 346,828.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 283,615.00 |
| Sep 30, 2024 | 243,343.00 |
| Jun 30, 2024 | 283,586.00 |
| Mar 31, 2024 | 210,483.00 |
| Dec 31, 2023 | 240,832.00 |
| Sep 30, 2023 | 448,558.00 |
| Jun 30, 2023 | 221,281.00 |
| Mar 31, 2023 | 259,180.00 |
| Dec 31, 2022 | 287,360.00 |
| Sep 30, 2022 | 202,778.00 |
| Jun 30, 2022 | 472,699.00 |
| Mar 31, 2022 | 280,680.00 |
| Dec 31, 2021 | 362,470.00 |
| Sep 30, 2021 | 248,485.00 |